Akers Biosciences Schedules Conference Call to Discuss Licensing Announcement with Premas Biotech for a Coronvirus Vaccine Ca...
March 24 2020 - 4:06PM
Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer
of rapid health information technologies, today announced it will
hold a conference call to discuss the licensing announcement with
Premas Biotech for a Coronvirus vaccine candidate.
Global biotech executive, co-founder and
managing director at Premas, Dr. Prabuddha Kundu M.D., will discuss
the process underway to seek fast track development of a vaccine
candidate and related milestones that we hope to achieve and plan
to announce as we progress.
Conference Call Information:
Date: Wednesday, March 25, 2020Time: 11:00 A.M.
Eastern Time (ET)Dial in Number for U.S. Callers:
1-877-407-9716Dial in Number for International Callers:
1-201-493-6779Conference ID: 13701016
The call will also be accompanied live by
webcast over the Internet and accessible at
http://public.viavid.com/index.php?id=138778. The webcast will be
available for one year.
A replay will be available for one week starting
on March 25, 2020 at approximately 2:00 P.M. ET. To access the
replay, please dial 1-844-512-2921 in the U.S. and 1-412-317-6671
for international callers. The conference ID# is 13701016.
About Akers Biosciences Inc.
Akers Biosciences is pursuing the development of
a newly acquired license to a coronavirus vaccine candidate. In
addition, the company develops, manufactures, and supplies rapid,
point of care screening and testing products designed to bring
health related information directly to the patient or clinician in
a timely and cost-efficient manner. Akers has previously announced
that that it had identified the hemp and minor cannabinoid sectors
as promising adjacent opportunities that could benefit from Akers’
existing facility and its core competencies.
Forward-Looking Statements
Statements in this press release relating to
plans, strategies, trends, specific activities or investments, and
other statements that are not descriptions of historical facts and
may be forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include any risks
detailed from time to time in Akers' reports filed with the
Securities and Exchange Commission, Annual Reports on Form 10-K,
Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K.
Forward-looking statements may be identified by terms such as
"may," "will," "expects," "plans," "intends," "estimates,"
"potential," or "continue," or similar terms or the negative of
these terms. Although Akers believes the expectations reflected in
the forward-looking statements are reasonable, they cannot
guarantee that future results, levels of activity, performance or
achievements will be obtained. Akers does not have any obligation
to update these forward-looking statements other than as required
by law.
Additional information on the company and its
products can be found at www.akersbio.com.
Contact:
Investor Relations: Hayden IRBrett Mass,
Managing PartnerPhone: (646) 536-7331Email: brett@haydenir.com
www.haydenir.com
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Aug 2024 to Sep 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Sep 2023 to Sep 2024